112 related articles for article (PubMed ID: 9061206)
1. Discovery of OT4003, a novel, potent, and orally active cys-LT1 receptor antagonist.
Tvaermose-Nielsen O; Rachlin S; Dannacher H; Björkling F; Kirstein D; Bramm E; Nielsen CK; Mortensen JT; Binderup L
Bioorg Med Chem; 1997 Feb; 5(2):415-27. PubMed ID: 9061206
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist.
Jones TR; Labelle M; Belley M; Champion E; Charette L; Evans J; Ford-Hutchinson AW; Gauthier JY; Lord A; Masson P
Can J Physiol Pharmacol; 1995 Feb; 73(2):191-201. PubMed ID: 7621356
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and structure-activity relationships of carboxyflavones as structurally rigid CysLT1 (LTD4) receptor antagonists.
Zwaagstra ME; Timmerman H; van de Stolpe AC; de Kanter FJ; Tamura M; Wada Y; Zhang MQ
J Med Chem; 1998 Apr; 41(9):1428-38. PubMed ID: 9554876
[TBL] [Abstract][Full Text] [Related]
4. Development of a novel series of styrylquinoline compounds as high-affinity leukotriene D4 receptor antagonists: synthetic and structure-activity studies leading to the discovery of (+-)-3-[[[3-[2-(7-chloro-2-quinolinyl)-(E)-ethenyl]phenyl][[3- (dimethylamino)-3-oxopropyl]thio]methyl]thio]propionic acid.
Zamboni R; Belley M; Champion E; Charette L; DeHaven R; Frenette R; Gauthier JY; Jones TR; Leger S; Masson P
J Med Chem; 1992 Oct; 35(21):3832-44. PubMed ID: 1331447
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist.
Jones TR; Zamboni R; Belley M; Champion E; Charette L; Ford-Hutchinson AW; Frenette R; Gauthier JY; Leger S; Masson P
Can J Physiol Pharmacol; 1989 Jan; 67(1):17-28. PubMed ID: 2540892
[TBL] [Abstract][Full Text] [Related]
6. The development of a novel series of (quinolin-2-ylmethoxy)phenyl-containing compounds as high-affinity leukotriene receptor antagonists. 3. Structural variation of the acidic side chain to give antagonists of enhanced potency.
Galemmo RA; Johnson WH; Learn KS; Lee TD; Huang FC; Campbell HF; Youssefyeh R; O'Rourke SV; Schuessler G; Sweeney DM
J Med Chem; 1990 Oct; 33(10):2828-41. PubMed ID: 2170649
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological profile of CR3465, a new leukotriene CysLT1 receptor antagonist with broad anti-inflammatory activity.
Ferrari F; Mennuni L; Caselli G; Zanelli T; Makovec F
Eur J Pharmacol; 2004 Nov; 504(3):223-33. PubMed ID: 15541426
[TBL] [Abstract][Full Text] [Related]
8. Stereospecific synthesis, assignment of absolute configuration, and biological activity of the enantiomers of 3-[[[3-[2-(7-chloroquinolin-2-yl)-(E)-ethenyl]phenyl] [[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]propionic acid, a potent and specific leukotriene D4 receptor antagonist.
Gauthier JY; Jones T; Champion E; Charette L; Dehaven R; Ford-Hutchinson AW; Hoogsteen K; Lord A; Masson P; Piechuta H
J Med Chem; 1990 Oct; 33(10):2841-5. PubMed ID: 2170650
[TBL] [Abstract][Full Text] [Related]
9. N-[(arylmethoxy)phenyl] carboxylic acids, hydroxamic acids, tetrazoles, and sulfonyl carboxamides. Potent orally active leukotriene D4 antagonists of novel structure.
Musser JH; Kreft AF; Bender RH; Kubrak DM; Grimes D; Carlson RP; Hand JM; Chang J
J Med Chem; 1990 Jan; 33(1):240-5. PubMed ID: 2104935
[TBL] [Abstract][Full Text] [Related]
10. The pharmacology of LY290324 in the guinea-pig: an orally active, potent and selective cysteinyl leukotriene receptor antagonist.
Boot JR; Bond A; Thomas KH; O'Brien A; Gilmore J; Todd A
Eur J Pharmacol; 1993 Jan; 231(1):83-9. PubMed ID: 8383064
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of the leukotriene antagonist verlukast: the (R)-enantiomer of MK-571.
Jones TR; Zamboni R; Belley M; Champion E; Charette L; Ford-Hutchinson AW; Gauthier JY; Leger S; Lord A; Masson P
Can J Physiol Pharmacol; 1991 Dec; 69(12):1847-54. PubMed ID: 1666333
[TBL] [Abstract][Full Text] [Related]
12. Development of a novel series of (2-quinolinylmethoxy)phenyl-containing compounds as high-affinity leukotriene receptor antagonists. 1. Initial structure-activity relationships.
Youssefyeh RD; Magnien E; Lee TD; Chan WK; Lin CJ; Galemmo RA; Johnson WH; Tan J; Campbell HF; Huang FC
J Med Chem; 1990 Apr; 33(4):1186-94. PubMed ID: 2157009
[TBL] [Abstract][Full Text] [Related]
13. Persistent airway eosinophilia after leukotriene (LT) D4 administration in the guinea pig: modulation by the LTD4 receptor antagonist, pranlukast, or an interleukin-5 monoclonal antibody.
Underwood DC; Osborn RR; Newsholme SJ; Torphy TJ; Hay DW
Am J Respir Crit Care Med; 1996 Oct; 154(4 Pt 1):850-7. PubMed ID: 8887574
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of 3H-leukotriene D4 binding to guinea pig lung receptors by the novel leukotriene antagonist ICI 198,615.
Aharony D; Falcone RC; Krell RD
J Pharmacol Exp Ther; 1987 Dec; 243(3):921-6. PubMed ID: 2826761
[TBL] [Abstract][Full Text] [Related]
15. A novel photoaffinity probe for the LTD4 receptor.
Gallant M; Sawyer N; Metters KM; Zamboni RJ
Bioorg Med Chem; 1998 Jan; 6(1):63-72. PubMed ID: 9502106
[TBL] [Abstract][Full Text] [Related]
16. Binding of radiolabeled high affinity antagonist to leukotriene D4 receptor in guinea pig lung membranes: interconversion of agonist-receptor binding affinity states.
O'Sullivan BP; Mong S
Mol Pharmacol; 1989 Jun; 35(6):795-802. PubMed ID: 2543913
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological profile of the novel, potent and selective peptide leukotriene antagonist (E)-2,2-diethyl-3'-[2-[2-(4-isopropyl)thiazolyl]ethenyl]succinanilic acid.
Yamada N; Yamada K; Takahashi K; Nakao E; Kadowaki S; Umezu K
Arzneimittelforschung; 1994 Jun; 44(6):749-53. PubMed ID: 8053974
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and SAR of a novel, potent and structurally simple LTD4 antagonist of the quinoline class.
von Sprecher A; Gerspacher M; Beck A; Kimmel S; Wiestner H; Anderson GP; Niederhauser U; Subramanian N; Bray MA
Bioorg Med Chem Lett; 1998 Apr; 8(8):965-70. PubMed ID: 9871521
[TBL] [Abstract][Full Text] [Related]
19. A series of non-quinoline cysLT1 receptor antagonists: SAR study on pyridyl analogs of Singulair.
Guay D; Gauthier JY; Dufresne C; Jones TR; McAuliffe M; McFarlane C; Metters KM; Prasit P; Rochette C; Roy P; Sawyer N; Zamboni R
Bioorg Med Chem Lett; 1998 Mar; 8(5):453-8. PubMed ID: 9871597
[TBL] [Abstract][Full Text] [Related]
20. Leukotriene C4 induces bronchoconstriction and airway vascular hyperpermeability via the cysteinyl leukotriene receptor 2 in S-hexyl glutathione-treated guinea pigs.
Yonetomi Y; Sekioka T; Kadode M; Kitamine T; Kamiya A; Matsumura N; Fujita M; Kawabata K
Eur J Pharmacol; 2015 May; 754():98-104. PubMed ID: 25704617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
